Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 0.82 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.82 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.82 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.82 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.70 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.64 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.64 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.64 |
| ▸ | AMD1 | P17707 | 3/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.54 |
| ▸ | DPP4 | P27487 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.54 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.54 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.54 |
| ▸ | GAPDH | P04406 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9940772 | 1.00 | PI4KA (0.82) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL19711603 | 1.00 | PI4KA (0.82) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL20152361 | 1.00 | PI4KA (0.82) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL16128949 | 1.00 | PI4KA (0.82) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL12899828 | 1.00 | PI4KA (0.82) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL460252 | 1.00 | PI4KA (0.82) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL16128942 | 1.00 | PI4KA (0.82) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL12928304 | 1.00 | PI4KA (0.82) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL20155850 | 1.00 | PI4KA (0.82) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL29407102 | 1.00 | PI4KA (0.82) | PI4KAPI4K2BPI4K2API4KBRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753433-B2 | Methods of synthesizing substituted purine compounds | Epizyme, Inc. (US) | 2023-09-12 | — | — | US | claimed |
| US-20210363171-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS | Epizyme, Inc. | 2021-11-25 | — | — | US | claimed |
| US-10968247-B2 | Methods of synthesizing substituted purine compounds | Epizyme, Inc. (US) | 2021-04-06 | — | — | US | claimed |
| US-20190300562-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS | Epizyme, Inc. | 2019-10-03 | — | — | US | claimed |
| US-20190300561-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS | Epizyme, Inc. | 2019-10-03 | — | — | US | claimed |
| US-20180134744-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS | Epizyme, Inc. | 2018-05-17 | — | — | US | claimed |
| US-9738679-B2 | Methods of synthesizing substituted purine compounds | Epizyme, Inc. (US) | 2017-08-22 | — | — | US | claimed |
| US-20160024134-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS | Epizyme, Inc. | 2016-01-28 | — | — | US | claimed |
| EP-2968387-A2 | METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS | Epizyme, Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| US-9175032-B2 | Methods of synthesizing substituted purine compounds | Epizyme, Inc. (US) | 2015-11-03 | — | — | US | claimed |
| US-20150011495-A1 | Methods of Synthesizing Substituted Purine Compounds | Epizyme, Inc. (US) | 2015-01-08 | — | — | US | claimed |
| WO-2014152566-A2 | METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS | Epizyme, Inc. (US) | 2014-09-25 | — | — | WO | claimed |
| US-12391768-B2 | Antibodies to ticagrelor and methods of use | MEDIMMUNE LIMITED (GB) | 2025-08-19 | — | — | US | disclosed |
| EP-2614369-B2 | METHOD FOR DETERMINING THE SUITABILITY OF INHIBITORS OF HUMAN EZH2 IN TREATMENT | EPIZYME INC (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20240247024-A1 | INHIBITORS OF NICOTINAMIDE N-METHYL TRANSFERASE (NNMT) | UNIVERSITEIT LEIDEN (NL) | 2024-07-25 | — | — | US | disclosed |
| US-20240101712-A1 | ANTIBODIES TO TICAGRELOR AND METHODS OF USE | MEDIMMUNE LTD (GB) | 2024-03-28 | — | — | US | disclosed |
| WO-2006078752-A2 | INHIBITORS OF DNA METHYLTRANSFERASE | METHYLGENE, INC. (CA) | 2006-07-27 | — | — | WO | disclosed |
| US-5864033-A | ENZYME INHIBITORS WITH HETEROCYCLIC BASES | METABASIS THERAPEUTICS, INC. (US) | 1999-01-26 | — | — | US | disclosed |
| US-5646128-A | TREATING INFLAMMATION, SEPSIS, SEPTIC SHOCK, BURNS | GENSIA, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1992012718-A1 | ADENOSINE KINASE INHIBITORS | GENSIA, INC. (US) | 1992-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011495-A1 | Methods of Synthesizing Substituted Purine Compounds | DOT1L, MECP2, TDP1 | PI4KA 3857/4885PI4K2B 3873/4885PI4K2A 3832/4885 |
| US-20160024134-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS | DOT1L, MECP2, TDP1 | PI4KA 3857/4885PI4K2B 3873/4885PI4K2A 3832/4885 |
| US-20240247024-A1 | INHIBITORS OF NICOTINAMIDE N-METHYL TRANSFERASE (NNMT) | NNMT, NAMPT, NNT | PI4KA 3391/4885PI4K2B 3804/4885PI4K2A 4007/4885 |
| US-20190300562-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS | DOT1L, MECP2, TDP1 | PI4KA 3857/4885PI4K2B 3873/4885PI4K2A 3832/4885 |
| US-20210363171-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS | DOT1L, MECP2, TDP1 | PI4KA 3857/4885PI4K2B 3873/4885PI4K2A 3832/4885 |
| US-20240101712-A1 | ANTIBODIES TO TICAGRELOR AND METHODS OF USE | NT5C2, GP6, P2RY6 | PI4KA 2317/4885PI4K2B 3721/4885PI4K2A 3441/4885 |
| US-12391768-B2 | Antibodies to ticagrelor and methods of use | NT5C2, GP6, P2RY6 | PI4KA 2317/4885PI4K2B 3721/4885PI4K2A 3441/4885 |
| US-10968247-B2 | Methods of synthesizing substituted purine compounds | DOT1L, MECP2, TDP1 | PI4KA 3857/4885PI4K2B 3873/4885PI4K2A 3832/4885 |
| US-20180134744-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS | DOT1L, MECP2, TDP1 | PI4KA 3857/4885PI4K2B 3873/4885PI4K2A 3832/4885 |
| US-20190300561-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS | MECP2, DOT1L, DNMT1 | PI4KA 3596/4885PI4K2B 3781/4885PI4K2A 3729/4885 |
| US-11753433-B2 | Methods of synthesizing substituted purine compounds | DOT1L, MECP2, TDP1 | PI4KA 3857/4885PI4K2B 3873/4885PI4K2A 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.